HLS Therapeutics Secures Agreement for Vascepa to Improve Cardiovascular Care in Nova Scotia
- HLS Therapeutics Inc. secured a Product Listing Agreement for Vascepa in Nova Scotia, effective July 1, 2025.
- The agreement ensures public reimbursement, enhancing access for over 95% of eligible Canadian patients.
- HLS is committed to improving cardiovascular care and patient outcomes through innovative therapies and expanded access.
HLS Therapeutics Secures Key Agreement to Enhance Cardiovascular Care in Nova Scotia
HLS Therapeutics Inc. recently announces a pivotal Product Listing Agreement (PLA) with the province of Nova Scotia, set to take effect on July 1, 2025, for its drug Vascepa (icosapent ethyl). This agreement allows for the public reimbursement of Vascepa as an exceptional status product under the Nova Scotia Pharmacare formulary. The drug plays a crucial role in the secondary prevention of cardiovascular events, targeting patients who are already on statin therapy and have established cardiovascular disease alongside elevated triglyceride levels. This proactive step is part of HLS's strategy to combat cardiovascular diseases, which remain a leading cause of morbidity and mortality.
The agreement significantly broadens the accessibility of Vascepa, ensuring that over 95% of eligible patients in Canada, covered by public plans and private insurance, can benefit from this important therapeutic option. The significance of this PLA is underscored by the high prevalence of cardiovascular diseases and the urgent need for effective interventions that can help prevent serious health complications. By enhancing the availability of Vascepa, HLS Therapeutics Inc. demonstrates its commitment to addressing pressing health challenges and improving patient outcomes in the region.
This development aligns with a growing recognition of the importance of managing triglyceride levels as part of a comprehensive cardiovascular care strategy. Vascepa has been shown to reduce the risk of cardiovascular events such as death, myocardial infarction, stroke, and the need for coronary revascularization. As the healthcare landscape continues to evolve, HLS's initiative reflects a proactive approach to ensuring that patients receive the medications necessary for effective disease management and prevention.
In addition to this significant agreement, HLS Therapeutics Inc. continues to explore avenues for expanding its product offerings and improving patient access to innovative therapies. The company is committed to addressing the needs of patients with cardiovascular conditions, thereby reinforcing its position as a key player in the healthcare sector focused on improving public health outcomes. This PLA marks a crucial step in HLS's mission to enhance the quality of care available to patients at risk of cardiovascular events.